Leukocytes may have 2 opposing effects in intravenous rtPA treatment for ischemic stroke.
We hypothesized that leukocytes have 2 opposing effects on patients with ischemic stroke treated with recombinant tissue plasminogen activator (rtPA). Patients with ischemic stroke treated with rtPA were divided into 2 groups using the peripheral leukocyte count: high leukocyte group (HLG) and low leukocyte group (LLG) and were evaluated with the National Institutes of Health stroke scale (NIHSS) during the first 24 hours. We defined significant improvement (SI) as NIHSS improving by more than 50% from the baseline, and deterioration following improvement (DFI) as the achievement of SI within 24 hours but its subsequent loss at 24 hours. Fifty-three patients were enrolled, and the rate of SI within 24 hours was higher in HLG than in LLG (85.2% vs 42.3%, P = .0011). However, the rate of DFI was significantly higher in HLG than in LLG (29.6% vs 7.7%, P = .0413). We found that leukocytes might have not only deleterious but also beneficial effects in intravenous rtPA treatment.
1Department of Neurology, Suiseikai Kajikawa Hospital, Hiroshima, Japan.
Eiichi
E
Nomura
Hiromitsu
H
Naka
Shinichi
S
Wakabayashi
Hiroshi
H
Kajikawa
Masayasu
M
Matsumoto
D000368:Aged; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007962:Leukocytes / Q000473:pathology*; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage; D020521:Stroke / Q000097:blood* / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator